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Abstract: Cancer, a fatal disease, is also one of the main causes of death worldwide. Despite various 
developments to prevent and treat cancer, the side effects of anticancer drugs remain a major con-
cern. Ascorbic acid is an essential vitamin required by our bodies for normal physiological function 
and also has antioxidant and anticancer activity. Although the body cannot synthesize ascorbic acid, 
it is abundant in nature through foods and other natural sources and also exists as a nutritional food 
supplement. In anticancer drug development, ascorbic acid has played an important role by inhib-
iting the development of cancer through various mechanisms, including scavenging reactive oxy-
gen species (ROS), selectively producing ROS and encouraging their cytotoxicity against tumour 
cells, preventing glucose metabolism, serving as an epigenetic regulator, and regulating the expres-
sion of HIF in tumour cells. Several ascorbic acid analogues have been produced to date for their 
anticancer and antioxidant activity. The current review summarizes the mechanisms behind ascor-
bic acid's antitumor activity, presents a compilation of its derivatives and their biological activity as 
anticancer agents, and discusses delivery systems such as liposomes, nanoparticles against cancer, 
and patents on ascorbic acid as anticancer agents. 
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1. Introduction 
In 2018, the World Health Organization (WHO) estimated that 9.6 million people 
died from cancer, which is expected to cause 16.4 million deaths by 2040 [1,2]. Although 
there has been progress in cancer research to reduce mortality and improve the survival 
rate, cancer still accounts for nearly one in every six deaths and is the second leading cause 
of death worldwide [1]. There have been numerous approaches such as chemotherapy, 
radiotherapy and surgery to prevent and treat cancer, and some signs of progress have 
been made, but the need to develop pioneering, effective treatments for cancer still exists 
[3,4]. The prevalence of side effects and adverse drug reactions is the problem associated 
with existing cancer treatments [5]. The most common side effects are nausea, vomiting, 
hair loss, diarrhoea, anaemia, fatigue, and appetite and weight changes, and in long-term 
use, the treatments can cause permanent gastrointestinal dysfunction and damage to the 
reproductive system [6,7]. Thus, finding new and effective drugs with fewer side effects 
is necessary for cancer treatment. Ascorbic acid (Figure 1) is a vital micronutrient in our 
bodies, possessing antioxidant [8–10] and anticancer activity [8,10]. 
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Figure 1. Chemical structure of ascorbic acid. 
Humans are incapable of producing ascorbic acid in their bodies due to the absence 
of the enzyme gluconolactone oxidase, which is required for the generation of ascorbic 
acid from glucose and galactose [11]. Hence, it is essential for humans to take ascorbic acid 
through their diet from various sources to meet their physiological needs. Sources of 
ascorbic acid for human diets including the following. 
1.1. Natural Sources 
Ascorbic acid is also known as vitamin C, which is widely found in citrus fruits, 
strawberries, tomatoes, broccoli, Brussels sprouts, green peppers, red peppers, turnips, 
and other leafy vegetables [12–14]; small amounts have also been found in fish and milk 
(Figure 2) [12].  
1.2. Dietary Supplements 
Ascorbic acid is available as a health supplement in different formulations such as 
powders for oral suspension, capsules, granules for oral solution, powders for oral solu-
tion, tablets, oral drops, and syrups in combination with proteins, omega-3 fatty acids, 
sugar, vitamin A, B1, B2, D, E, methylcobalamin (B12), pyridoxine (B6), niacin (B3), biotin 
(B7), pantothenic acid (B5), folic acid (B9), L-arginine, calcium, copper, iodine, iron, mag-
nesium, phosphorus, potassium, selenium, sodium, and zinc (Figure 2) [15]. Sometimes, 
in dietary supplements, ascorbic acid may contain mineral ascorbates in the form of cal-
cium ascorbate or sodium ascorbate [16].  
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Figure 2. Sources of ascorbic acid. 
Subject to dose and route of administration, ascorbic acid exhibits either antioxidant 
or anticancer activity; at lower concentrations, it functions as an antioxidant, and at higher 
pharmacological concentrations, as a pro-oxidant [10].  
Ascorbic acid plays the role of an antioxidant agent by reducing unstable free radicals 
of oxygen, nitrogen, and sulphur and also by enhancing the activity of another antioxi-
dant, tocopherol (vitamin E) [17]. Thus, ascorbic acid protects DNA, amino acid residues, 
and lipids from oxidation induced by free radicals and maintains their integrity [18], pre-
venting them from harmful mutations. At pharmacological concentrations, ascorbic acid 
generates H2O2 in cancer cells [19] through organometallic reaction [20] and causes selec-
tive cytotoxicity to cancer cells [19]. About 90% of cancer deaths are rooted in metastasis; 
in metastasis, cancerous cells are spread from the primary tumour site to surrounding 
tissues and distant organs through the blood and lymphatic vessels [21–23]. Cancer be-
comes highly fatal and incurable after spreading beyond the primary tumour site [21]. In 
in vitro study, it was observed that ascorbic acid at high concentration curbed cell migra-
tion and capillary-like tube formation [24]. Accordingly, ascorbic acid can be useful to 
prevent the further growth and spread of tumour cells. Moreover, ascorbic acid not only 
protects our body from free radicals as an antioxidant and damages cancerous cells as a 
pro-oxidant, but it is also involved in many important physiological functions such as the 
formation of collagen, wound healing, repair of body tissues, and nurturing of bones, car-
tilage, and teeth [25]. In addition, ascorbic acid is less toxic towards the normal cells [26] 
and it is cheap and easily available; therefore, it could be an ideal agent to develop an 
anticancer agent. This up-to-date review focuses on the importance of ascorbic acid to 
improve cancer remedies. It focuses on recent advances and reviews the biological activity 
of various ascorbic derivatives as anticancer and antioxidant agents on different cell lines. 
2. Metabolism 
Physiologically, ascorbic acid exists in L- ascorbic acid and L-dehydroascorbic acid 
configurations [12]. On oxidation, L-dehydroascorbic acid irreversibly gives 2, 3-diketo-
L-gulonic acid [12,13,27], which is then converted to C5 aldonic acids followed by D-xylu-
lose 5-P; later enter in key metabolism through the pentose phosphate pathway. Also, 2, 
3-diketo-L-gulonic acid is also converted to L-erythrulose, which next is promoted to 3-
deoxythreosone [27]. During metabolism, due to its complex chemical nature, L-dehy-
droascorbic acid can produce several products that may contribute to body physiology 
and also to disease pathology, including 3- deoxythreosone, a reactive agent that glycates 
lens proteins, and oxalates that contribute to the development of kidney stones by forming 
calcium oxalate (Figure 3) [27]. The metabolites of ascorbic acid are primarily eliminated 
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through urine [13]. It is pertinent to mention here the SVCT role in mediating the transport 
of ascorbate into the cell for activation [28].  
 
Figure 3. Degradation of ascorbic acid into various products during metabolism. 
3. Structural Features  
Ascorbic acid is a five-membered gamma-lactone ring sugar acid, containing four 
hydroxyl groups at different positions. The C2 and C3 hydroxyl groups of L-ascorbic acid 
linked with its C1 carbonyl group make the proton on the C3 hydroxyl group suggestively 
acidic (pK1 = 4.25) in comparison to the C2 hydroxyl group proton (pK2 = 11.79). At phys-
iological pH, it exists in the form of ascorbate anion, which is a good reducing agent that 
is oxidized into ascorbate free radical and later into dehydroascorbate [29,30]. The C5 and 
C6 hydroxyl groups are typical alcohol groups that form acetals and ketals on reaction 
with aldehydes and ketones, respectively. The two asymmetric centres at C4 and C5 of L-
ascorbic acid are responsible for positive optical rotation (Figure 4) [29]. The two asym-
metric centres are also responsible for different diastereoisomers such as L-ascorbic acid 














Figure 4. Numbering of the different carbon atom of L-ascorbic acid (4R, 5S). 
4. Possible Interventions in Cancer Treatment 
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In 1976, when Ewan Cameron and Linus Pauling reported that ascorbic acid admin-
istration to cancer patients increased their survival rates [31], ascorbic acid drew signifi-
cant attention for its potential to possess anticancer activity. Subsequently, several studies 
have been approved to assess the anticancer potential of ascorbic acid. In cancer, the af-
fected cells further invade normal cells in different parts of the body. Cancer cells have 
several aids for growth and invasion: namely, glucose transporters (GLUTs), hypoxia-in-
ducible factor (HIF), and ten-eleven translocation (TET) proteins. GLUTs transport glu-
cose to cancer cells, enhancing growth and invasion (Figure 5). HIF controls the expression 
of genes linked to angiogenesis, anti-apoptotic activity, stem cell renewal, metastasis, and 
therapeutic resistance of cancer cells. TET proteins are associated with the activation of 
cancer stem cells by altering the metabolic and epigenetic profiles of cells. Finding novel 
characteristics of ascorbate with pathways it controls in cancer will assist in the selection 
and development of innovative therapies. In light of its anticancer potential, studies sup-
port that ascorbate is linked to the crucial functions of the GLUT, HIF, and TET mecha-
nisms. From different studies, it was observed that ascorbic acid combats cancer by the 
following mechanisms of action: 
 
Figure 5. The different mechanisms involved in the interventions of ascorbic acid as an anticancer 
agent. 
4.1. As the down Regulator of Hypoxic Inducible Factors 
Oxygen deficiency with severe hypoxia has been observed in cancer patients [32]. 
The constant O2 deprivation in cells induces stimulation of hypoxia-inducible factors 
(HIF) [33,34], which transform the expression of numerous genes, resulting in angiogene-
sis and development of erythropoietic stem cells [33]. In normoxic environments, HIF ex-
pression is strongly controlled by special oxygen-responsive prolyl hydroxylase domain 
enzymes (PHDs); these enzymes hydroxylate the proline residues of HIFs and regulate 
HIF activity [32–35]. In addition, under normoxic conditions factor inhibiting HIF (FIH) 
also regulates HIF-1α activity through hydroxylating asparagine residues of HIF-1α by 
obstructing the recruitment of coactivator p300, which leads to transcriptional inactivation 
of HIF-1α [36]. The PHD-induced hydroxylation process is very important, as it is in-
volved in the proteasomal destruction of ubiquitinated HIF-1α by von Hippel-Lindau 
(VHL) protein [34,35,37]. The VHL protein identifies hydroxylated HIF and binds to it, 
then accumulates the ubiquitin ligase, resulting in cleavage of HIF-1α [37,38]. Because the 
PHD and FIH use oxygen as a substrate, under hypoxic conditions the process cannot take 
place [39], leading to activation of HIF. PHDs are a class of dioxygenases, requiring iron 
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and 2-oxoglutarate to exert activity [34,40]. Ascorbate acts as a co-factor to the PHDs to 
recycle and maintain ferrous ion (Fe2+) [40,41]. Therefore, the presence of ascorbate can 
impact HIF function, which in turn can affect tumour progression [40]. Wilkes et al. have 
revealed that pharmacological ascorbate induced degradation of HIF-1α, leading to de-
creased metastatic development in pancreatic cancer [42]. At higher doses, ascorbic acid 
reduces DNA damage and mutations through degradation of HIF-1α levels (Figure 6) 
[43]. This suggests that ascorbate at higher doses in cancer cells inhibits HIF-1α activity 
by enhancing the action of HIF hydroxylases, thus suppressing tumour growth. 
 
Figure 6. Ascorbate regulates HIF-1α by recycling Fe2+ required for the function of PHDs and FIH, 
leading to alteration of cancer progression [34,35,37,41,42]. 
4.2. Impairing Glucose Metabolism in Cancer Cells  
In the early 1900s, Otto Warburg and co-workers observed that a higher amount of 
glucose was consumed for glycolysis by tumour cells in the absence of abundant oxygen; 
this is known as the Warburg Effect [44]. It is a crucial characteristic of tumour survival 
and proliferation in hypoxic environments [45]. This change in glycolytic character allows 
tumour cells to undergo 200 times faster rates of glycolysis than normal cells [46]. The 
Warburg Effect is a vital metabolic trait of cancer cells [47]. Yu et al. have observed that 
mutations of KRAS or BRAF genes in cancer cells upregulate glucose transporter-
1(GLUT1) genes promoting the Warburg effect [48]. Under low glucose conditions, cancer 
cells survive through increased glycolysis resulting from selective upregulation of 
GLUT1, which could be a potential approach to treat cancer [49]. It was perceived that 
intravenous high concentrations of ascorbic acid selectively interfere with mutated KRAS 
or BRAF, inducing GLUT1 regulation of glycolysis and killing cancer cells. After admin-
istration into the body, ascorbic acid oxidizes to dehydroascorbate (DHA) [50]. Due to its 
structural similarity to glucose, DHA is taken up by KRAS or BRAF mutated GLUT1 in 
cancer cells [41]. Once it enters the cell, DHA in the presence of nicotinamide adenine 
dinucleotide phosphate (NADPH) and glutathione (GSH) is reduced back to ascorbic acid 
[50]. In this reduction process, the alteration of GSH and NADPH to glutathione disul-
phide (GSSG) and oxidized nicotinamide adenine dinucleotide phosphate (NADP+), re-
spectively, gives rise to cellular ROS [50,51]. The raised ROS level damages DNA guiding 
activation of poly (ADP-ribose) polymerase (PARP), which depletes nicotinamide adenine 
dinucleotide (NAD+), an important cofactor for the conversion of glyceraldehyde 3-
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phosphate dehydrogenase (GAPDH) to nicotinamide (NAM). This hindrance of GAPDH 
in KRAS or BRAF mutant cells leads towards scarcity of energy followed by cell death as 
mitochondria produce less ATP [50]. In gastric and renal cancer, it was observed that there 
is high expression of GLUT1 with higher glycolytic activity and that they are sensitive to 
high doses of ascorbate treatment, resulting in the selective killing of cancer cells (Figure 
7) [52,53]. Hence, ascorbic acid can induce toxicity in cancer cells by impairing glucose 
metabolism. 
 
Figure 7. Role of ascorbate in impairing glucose metabolism in cancer cells [41,46,51–53]. 
4.3. As an Epigenetic Regulator  
Altered genetic and epigenetic profiles caused cancer and cancer progression [54]. In 
epigenetic modifications, there are not any direct variations in the DNA sequence; rather, 
there is an array of gene expression such as DNA methylation/demethylation [55]. Hypo-
methylation triggers various intranuclear transcription factors by which it promotes can-
cer formation [56], and hypermethylation facilitates tumorigenesis by confining promo-
tors of tumour suppressor genes [30,56,57]. Mutation and altered expression of ten-eleven 
translocation (TET) protein families [45] lead to abnormal DNA methylation, which con-
tributes to cancer formation [58]. In hematopoietic malignancies, TET (TET2) is commonly 
mutated [58]. TET proteins are iron/α-ketoglutarate-dependent dioxygenase (Fe2+/α-
KGDD) enzymes [59]; the family comprises TET1, TET2, and TET3 proteins [58]. These 
enzymes require cofactor ascorbic acid to exert their activity [18,60]. TET proteins catalyse 
the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which in 
later steps aids oxidation to aldehyde to form 5-formylcytosine (5fC) and carboxylic acid 
to form 5-carboxylcytosine (5CaC) [61,62]. Oxidized 5fC and 5CaC undergo base excision 
mechanism in the presence of thymine DNA glycosylase enzyme and are transformed to 
cytosine [63]. Throughout the enzymatic activity of TETs, ascorbate acts as a cofactor to 
promote the recovery of Fe3+ to Fe2+ (Figure 8) [64]. Different types of haematological ma-
lignancies such as acute myeloid leukaemia (AML) and chronic myelomonocytic leukae-
mia (CMML) are associated with mutation-led hindered catalytic activity of TET2 [65]. 
Shenoy et al. have observed that ascorbic acid in lymphoma patients modifies TET func-
tion by increasing the suppression of tumour suppressor gene SMAD1 and improved 
chemosensitivity [60]. Ascorbic acid in AML cells and TET2 deletion mouse models in-
duces DNA hypomethylation and elevated TET activity [59]. Thus, TET enzymes block 
Biomolecules 2021, 11, 1130 8 of 24 
 
significant protagonists in cancer progression and ascorbate accessibility impacts their ac-
tivity. 
 
Figure 8. Role of ascorbate in the regulation of TET enzymes [41,59,60,65]. 
4.4. As an Antioxidant Agent  
In the human body, reactive oxygen species (ROS) are generated during physiologi-
cal and pathological processes [66,67], but high levels of ROS contribute to carcinogenesis 
[68]. ROS attack cellular DNA, causing damage and genomic instability and leading to 
mutations that incorporate the development of neoplastic characteristics [69,70]. In 
healthy humans, ascorbate at 40–80 μM of plasma concentration exerts antioxidant activ-
ity; at this concentration, ascorbate donates an electron to free radicals and diminishes 
their potential damaging effects [30]. During this process, ascorbate is itself oxidized into 
a fairly unreactive ascorbate radical, which through NADH/NADPH-dependent reduc-
tases is converted back to ascorbate (Figure 9) [30]. Ascorbate in association with vitamin 
E synergistically functions as a co-antioxidant to shield LDL from ROS-induced lipid pe-
roxidation [30] and prevent the formation of the end-product of the process, 4-hy-
droxynonenal (HNE), which is considered as a secondary messenger of oxidative stress 
[45]. Ascorbate also maintains vitamin E levels in the body after the inhibition of lipid 
oxidation [71]. In addition, ascorbic acid supplementation as an antioxidant during chem-
otherapy increases tumour response to treatment and also increases survival rate [72]. Suh 
et al. have observed that ascorbate in vitro acts as an anti-oxidant by preventing iron-
induced lipid peroxidation [73]. Chen et al. have reported that orally supplemented ascor-
bate in guinea pigs with iron overload acts as an antioxidant by suppressing lipid oxida-
tion [74]. Thus, ascorbic acid at lower concentrations acts as an antioxidant to prevent 
damage caused by free radicals to the body and also prevents degradation of vitamin E 
by enhancing the effects of chemotherapy. 
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Figure 9. Antioxidant mechanism of ascorbic acid [40,41,71]. 
4.5. Pro-Oxidant Role  
Ascorbic acid at micromolar (μM) concentrations functions as an anti-oxidant agent, 
but at higher, millimolar (mM) concentrations, also functions as a pro-oxidant. Intrave-
nous administrations of vitamin C induce cytotoxicity to tumour cells [75], as it can pro-
duce 70-fold greater plasma concentration than its oral counterpart [76]. It was observed 
that the antitumor potential of high-dose ascorbic acid is rooted in its ability to generate 
hydrogen peroxide (H2O2) [77]. In animals, ascorbate at millimolar concentrations donates 
an electron to copper and iron metals, resulting in the production of superoxide, a hydro-
gen peroxide-like ROS [20]. The ROS induces damage to DNA, ultimately causing cyto-
toxicity to cancer cells [55]. Upon intravenous administration, ascorbate (AscH−) reacts 
with protein-centred transition metal ions, i.e., ferric (Fe3+) and cupric (Cu2+) ions. In prac-
tice, there is a fairly low level of conversion metals, and thus greater concentrations of 
vitamin C are necessitated. Ascorbate reduces Fe3+/Cu2+ to ferrous (Fe2+)/cuprous (Cu+) 
ions, oxidizing itself into ascorbate free radical (Asc−). The reduced Fe2+/Cu+ ions react 
with oxygen to form ROS such as superoxide radicals, which in the existence of hydrogen 
undergo dismutation and form hydrogen peroxide (H2O2). Further, the H2O2 may un-
dergo a Fenton-like reaction catalysed by Fe2+/Cu+, yielding hydroxyl peroxide radical 
(HO⋅) [30,55], which induces damage to cancer cells [78].  
AscH− + Fe3+/Cu2+ → Asc•− + Fe2+/Cu+  
Fe2+/Cu+ + O2 → Fe3+/Cu2+ + O2•−  
O2•− + O2•− + 2H+ → H2O2 + O2  
Fe2+/Cu+ + H2O2 → Fe3+/Cu2+ + HO•  
It was reported that tumour tissues contain proteins in interstitial fluid [79] and the 
damaged protein in extracellular fluid contains catalytic metals such as iron and copper 
[80]. Compared to normal endothelium, tumour vessels have greater permeability [79], 
which amplifies the metal ion required for catalytic conversion and enhances the trans-
formation of ascorbic acid to H2O2 [80]. Several studies have reported elevated copper 
levels in cancer [81,82], as it is a cofactor of DNA replication enzymes for rapidly prolifer-
ating cancer cells [55]. In cancer, elevated copper concentrations with an altered systemic 
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distribution of the element [83] made cancer cells vulnerable to the ROS-generated selec-
tive cytotoxicity of copper and ascorbic acid [84]. Additionally, in the case of iron, alt-
hough it is stored by the glycoprotein ferritin in healthy individuals, under pathological 
conditions such as cancer inflammation, extracellular iron chelates are increased in tissue 
[85], making them susceptible to ascorbate-induced ROS toxicity. 
Chen et al. have observed that ascorbic acid selectively hinders tumour growth with-
out causing any damage to normal cells via the generation of H2O2 [19]. Baek et al. also 
observed that ascorbic acid induces toxicity to cancer cells through the generation of ROS 
[86]. In another study, a high quantity of ascorbic acid prompted the cell death of malig-
nant cells through the generation of ROS, especially hydrogen peroxide [87]. Thus, ascor-
bic acid at millimolar concentrations induces toxicity to various cancer cells through the 
generation of ROS, which themselves damage cellular components and hamper various 
important cellular mechanisms.  
5. Potent Synthetic Derivatives of Ascorbic Acid against Cancer 
L-ascorbic acid possesses few susceptible sites available for substitution, generating 
a sum of compounds with of exciting chemical, physical, and biological characteristics. 
Previous accounts of ascorbic acid analogues substituted to C2, C3, C5, and C6 positions 
have been reported in various studies [88,89]. Designing new ascorbic acid analogues as 
anticancer agents follows derivatization on any of the above-mentioned sites and the eval-
uation of their activity against some of the following cell lines, such as hepatocellular car-
cinoma (HepG2), colorectal adenocarcinoma (SW620), lung adenocarcinoma (A549), col-
orectal carcinoma (HCT-116), breast adenocarcinoma (MCF-7), cervical carcinoma (HeLa), 
ductal pancreatic adenocarcinoma (CFPAC-1), murine colon carcinoma (Colon-26), mu-
rine leukaemia (L1210), pancreatic carcinoma (MiaPaCa-2), acute lymphoblastic leukae-
mia (CEM), Burkitt’s lymphoma (Raji line), myeloma (CCL155), colon cancer cells (HT29), 
hepatoma cells (HuH7), prostate cancer line (PC3), and non-small cell lung carcinoma (H-
460). Following are some of the ascorbic acid analogues evaluated as antitumor and anti-
oxidant agents. 
Macan et al. (2019) synthesized two sequences of 6-(1,2,3-triazolyl)-2,3-dibenzyl-L-
ascorbic acid analogues. Newly synthesized 6-(1,2,3-triazolyl)-6-deoxy-L-ascorbic acid 
and 6-(1,2,3-triazolyl)-4,5-didehydro-5,6-dideoxy-L-ascorbic acid analogues were as-
sessed for antiproliferative activity. Among all the synthesized derivatives, compound 1 
(Figure 10) (2,3-O, O-dibenzyl-6-(4-decyl-1,2,3-triazol-1-yl)-6-deoxy-L-ascorbic acid) dis-
played strong cytostatic activity, predominantly against breast adenocarcinoma cell lines 
(IC50 = 0.08 μM), while causing no toxicity to normal fibroblasts (IC50 > 100 mM). Com-
pound 1 induces cytotoxicity through regulation of the HIF-1α signalling pathway [90]. 
Harej et al. (2019) synthesized novel 4-substituted 1,2,3-triazole L-ascorbic acid de-
rivatives with hydroxy ethylene linkers and assessed their antiproliferative action. 
Among all the synthesized derivatives, compound 2 (Figure 10) (6-[4-(4-bromophenyl)-
1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid) showed the highest selectively antiprolifera-
tive activity towards breast adenocarcinoma cells (IC50 = 6.72 μM). In addition, compound 
2 was not cytotoxic towards foreskin fibroblasts and showed little cytotoxicity towards 
lung fibroblasts (IC50 = 73.93 μM). Compound 2 (IC50 = 6.72 μM) showed cytotoxicity 
higher than that of reference compound carboxyamidotriazole (IC50 = 14.69 μM) but lower 
than that of reference compound 5-fluorouracil (5-FU) (IC50 = 0.096 μM) against MCF-7 
cell lines. It was revealed that compound 2 exhibited cytotoxicity against MCF-7 cells 
through HIF-1-triggered hypoxia [91].  
Miura et al. (2018) synthesized 2-O-α-D-Glucopyranosyl-6-O-(2-Pentylheptanoyl)-L-
ascorbic acid (compound 3) (Figure 10) and evaluated its antitumor activity on cells and 
tumour-bearing animal models. It was reported that the synthesized derivative did not 
show cytotoxicity against colon-26 cells at a 2 mM concentration. However, when admin-
istered at 1.7 mmol/kg of intravenous (IV) doses on every alternate day for 4 times, com-
pound 3 inhibited tumour progression more strongly than control substances ascorbic 
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acid and 2-O-α-D-Glucopyranosyl-L-ascorbic acid, a steady ascorbic acid derivative, de-
spite comprising only 10 per cent of the molar amount of the control substance dose. This 
study suggested that compound 3 after administration converted to its metabolite AA-2G, 
which later oxidized to DHA and selectively killed the cancer cells through induction and 
increased endogenous oxidative stress [92].  
Babic et al. (2015) synthesized new halogenated 3-deazapurine, 7-deazapurine, alkyl-
ated 9-deazapurine analogues of L-ascorbic acid and imino-L-ascorbic acid. The newly 
created derivatives were assessed for antitumor activity, and it was observed that, among 
all synthesized analogues, compound 4 (Figure 10), a 9-deazapurine analogue of L-ascor-
bic acid, showed the highest inhibitory activity towards CEM cells (IC50 = 4.1 ± 1.8 μM) 
and strong inhibitory activity against L1210 cells (IC50 = 4.7 ± 0.1 μM). Additionally, com-
pound 5 (Figure 10) a 9-deazahypoxanthine analogue of L-ascorbic acid, demonstrated 
the highest antiproliferative activity against HeLa cells (IC50 = 5.6 ± 1.3 μM) and robust 
inhibitory activity against L1210 cells (IC50 = 4.5 ± 0.5 μM), whereas compound 6 (Figure 
10), a disubstituted 9-deazapurine analogue with two imino-L-ascorbic acid moieties, ex-
hibited the strongest inhibitory activity towards L1210 cells and MiaPaCa-2 cells (IC50 = 
4.4 ± 0.3 μM, IC50 = 5.7 ± 0.2 μM, respectively). In addition, compounds 4, 5, and 6 were 
not cytotoxic towards 3T3, a murine embryonal fibroblast cell (IC50 > 100 μM), as com-
pared to the standard drug, 5-fluorouracil (28.3 ± 0.01 μM) [93].  
Bordignon et al. (2013) synthesized ascorbic acid derivatives by addition of phos-
phate or adenine side chains to the furanic ring, yielding a structure similar to ATP, and 
evaluated their antiproliferative activity. Among the synthesized derivatives, it was ob-
served that compound 7 (Figure 10) (dibenzyl (S)-1-[(R)-3,4-bis(benzyloxy)-5-oxo-2,5-di-
hydrofuran-2-yl]-2-hydroxyethyl phosphate) exhibited the highest cytotoxicity towards 
HuH7, HT29, Raji and CCL155 cell line (IC50 = 0.1 ± 0.002, 0.15 ± 0.011, 0.086 ± 0.004 and 
0.1 ± 0.005 mM, respectively) without causing any cytotoxicity against normal human 
cells. Compound 7 was further studied on xenografted animals with two dissimilar hu-
man tumour cell lines, HT29 and PC3. At 10 mg/kg/d dose, compound 7 on PC3 xeno-
grafted mice notably lowered tumour development and tumour weight, leading to the 
survival of all compound 7 treated mice at the termination of the study, whereas only 6 of 
10 placebo-treated mice remained alive. The researchers also pointed out that compound 
7 inhibited tumours by suppressing the expression of translation initiation factor and 
tRNA synthetase [94].  
Wittine et al. (2012) synthesized new 1,2,4-triazole L-ascorbic acid, imidazole L-ascor-
bic acid, and imino-ascorbic acid derivatives and assessed their antitumor properties. 
Among all synthesized derivatives, compounds 8 and 9 (Figure 10) exhibited the greatest 
evident cytostatic effects towards entirely used tumour cell lines, and were selectively cy-
totoxic against CEM/0 cells (IC50 of 10 ± 4 and 7.3 ± 0.1 μM, respectively). Although com-
pound 9 was more active than compound 8, it showed no cytotoxicity towards human 
normal fibroblasts (IC50 > 100 μM) unlike compound 8 (IC50 = 73 ± 0.5 μM). Compound 8 
and 9 were both less cytotoxic than the reference drug doxorubicin (IC50 = 0.39 ± 0.21 μM) 
towards CEM/0 cells but more than another reference drug, ribavirin (IC50 = 63 ± 14 μM). 
They also observed that compound 8 exhibited an antitumor effect through inhibition of 
inosine 5’-monophosphate dehydrogenase (IMPDH) [95]. 
Gazivoda et al. (2007) synthesized two series of new C-5 alkynylated pyrimidine and 
fused bicyclic furo[2,3-d]pyrimidine analogues of ascorbic acid. The newly synthesized 
compounds' cytostatic activities were evaluated, and it was observed that from all the 
synthesized derivatives, compound 10 (Figure 10) showed the highest cytostatic activity 
against Molt4/C8, CEM, MiaPaCa-2, SW 620, MCF-7, and H-460 cell lines (IC50 = 3.0 ± 1.1, 
2.0 ± 0.3, 3 ± 0.5, 4 ± 0.3, 4 ± 1.4, and 2.4 ± 0.4 μM, respectively) [96]. 
Gazivoda et al. (2006) synthesized 5,6-di-O-modified L-ascorbic acid analogues and 
evaluated their cytostatic activity. It was reported that among all synthesized compounds, 
Z-2,3-Di-O-benzyl-6-chloro-4,5-didehydro-L-ascorbic acid (compound 11) (Figure 10) ex-
hibited prominent antitumor activity against all the malignant tumour cells with an IC50 
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of 18 ± 1 μM, while also exerting cytotoxicity towards human normal diploid fibroblasts 







Figure 10. Ascorbic acid analogues showing antitumor effects. 
From all of the above derivatives, it was observed that protecting 2,3-hydroxyl 
groups with bulky benzyl ether (benzyloxy) groups decreased polarity, which in turn pro-
moted the antitumor activity of the derivatives. The C1 carbonyl oxygen is essential to 
exert antitumor effects. In the case of compounds 4, 5, 8, 9, 10, and 11 (Figure 10), it was 
observed that unsaturation of the C4 carbon further increased antitumor activity. At the 
6th position, substitution with an electronegative element or aromatic ring increased the 
antitumor activity. Substitution or alteration with an electron-withdrawing group at po-
sitions 2, 3, 5, and 6 is vital for the antitumor potential of ascorbic acid (Figure 11). 
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Figure 11. Important structural features of ascorbic acid analogues showing antitumor effects. 
6. Emerging Trends in Cancer Therapy  
As a demand to enhance the effects of treatment, the integration of molecules into 
different encapsulated delivery systems is important, as it protects the molecule from 
chemical breakdown [98]. Various studies have displayed successful and effective inte-
gration of ascorbic acid and its analogues into encapsulated delivery systems; some of 
these are described below: 
6.1. Liposomes  
Liposomes are biodegradable, small, artificial, spherical vesicles created from natural 
or synthetic phospholipids and cholesterol [99,100]. The phospholipids and cholesterol 
that make up liposomes are amphipathic, consisting of a hydrophilic head and lipophilic 
tail [100,101]. The polar heads and the hydrophobic tails form a bilayer that aids them in 
entrapping lipid-soluble and water-soluble ingredients in the hydrophobic and hydro-
philic spheres, respectively [100]. Thus, owing to hydrophobic and hydrophilic character-
istics [99] they can tweak the pharmacokinetic characteristics of drugs, herbs, and proteins 
(Figure 12) [100]. 
 
Figure 12. Structure of liposome. 
Filipczak et al. developed liposomes composed of ammonium ascorbate, mitoxan-
trone (MTX), and anacardic acid. The invented liposomal preparations selectively magni-
fied the level of apoptosis in melanoma cell lines through specific production of free rad-
icals by an iron ion mechanism. Morphological studies revealed a consistent circular 
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shape with diameters spanning between 102 to 120 nm. The liposomal entrapped drugs 
are less toxic towards Hep-G2 and H9C2 cell lines in comparison to free drugs. After 12 
hr of administration of liposomes, the caspase activity was increased eight-fold against 
A375 melanoma, which led to generation of excessive reactive oxygen species, resulting 
in cell death [102].  
Yang et al. developed liposomes of palmitoyl ascorbate (PA) with doxorubicin 
(DOX). In some classes of cancer therapy, PA diminishes DOX-triggered toxicity. The lip-
osomes at high concentrations generate an increased quantity of ROS production and lead 
to the initiation of apoptosis. Morphological studies confirmed that the liposomes were 
spherical and homogeneous with a diameter ranging from 91 to 137.5 nm. Because PA 
prolonged plasma half-life, in vivo, it helps in extended drug retention. The liposomes 
containing PA and doxorubicin reduced the weights and sizes of the tumour by 2.5-fold 
and 5-fold compared to liposomes containing DOX and DOX in solution, respectively 
[103]. 
Li et al. developed a liposome co-delivery system of palmitoyl ascorbate (PA) with 
docetaxel (DC) for antitumor therapy. Synergistically, PA was used in combination with 
cytotoxic chemotherapy (DOC) to enhance its efficacy and cytotoxic activity. The drug-
loaded liposomes were uniform, with particle sizes ranging between 140 to 170 nm. In in 
vitro tests, the liposomes consisting of PA and DC at a 200:1 weight ratio exerted maxi-
mum synergistic effects towards MCF-7, PC-3, and HepG2 cell lines. In addition, they 
inhibited tumour cell progression in vivo more efficiently than liposomes consisting of 
either drug alone [104].  
Lipka et al. developed a coencapsulated epirubicin (EPI) liposome with ascorbic acid 
and ammonium ascorbate salt gradient. EPI, an antineoplastic agent, inhibits DNA and 
RNA synthesis by hindering topoisomerase II and is also liable for free radicals, resulting 
in toxicity against cancer cells. The drug-loaded liposomes are uniform with particle sizes 
ranging from 112 to 123 nm. The plasma abolition of free EPI is very fast compared to the 
liposome-encapsulated drug. In the case of the free drug, only 1% remains present in the 
plasma after 15 minutes, whereas for the encapsulated drug, about 40% is still present 
even after 24 hours. The liposomal encapsulated EPI with ascorbic acid gradient exhibited 
impressive antitumor activity in vivo against a breast cancer 4T-1 murine model [105]. 
6.2. Nanoparticles  
Nanoparticles (NPs) (Figure 13) are particles made up of a wide range of materials 
usually with particle sizes ranging from 1 to 100 nm [106,107]. Researchers have observed 
that the physiochemical properties of a substance are influenced by its particle size [106]. 
Cell absorb substances with sizes ranging between 1 and 10 μm [108,109]; thus, nanopar-
ticles owing to their size, easily enter the tissues and are absorbed by cells, ensuring effec-
tive drug action at the targeted location with reduced or insignificant side effects [110]. 
Therapeutically, nanoparticles are used to improve the dissolution, drug targeting, ab-
sorption, and breakdown of the enclosed compound and controlled release of the drugs 
[111]. 
 
Figure 13. Nanoparticles containing drug particles. 
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Zhou et al. in 2017 developed nanoparticles with a dual drug delivery approach for 
synergistic cancer treatment by encapsulating ascorbyl palmitate (AP) and paclitaxel 
(PTX) and evaluating their anticancer potential against the B16F10 cell line. Dynamic light 
scattering and transmission electronic microscopy (TEM) verified the globular profile of 
the nanoparticles, which had an average diameter of 223 nm and identical zeta potential. 
In vitro study revealed that AP/PTX-solid lipid nanoparticles (AP/PTX-SLNs) containing 
AP and PTX in a ratio of 2:1 exhibited an ideal anticancer synergistic effect with improved 
cellular permeability and uptake of AP and PTX. In comparison, in vivo study revealed 
that, in B16F10-tumour-bearing mice, AP/PTX-SLNs effectively suppressed tumour 
growth in the lungs and eliminated the cancer cells more effectively than either of the sole 
drug-filled SLNs through reduction of the Bcl-2/Bax fraction. In addition, throughout the 
study with AP/PTX-SLNs, no evident side effects were observed [112]. 
In 2014, Guney et al. entrapped ascorbic acid (AA) in solid lipid nanoparticles (SLNs) 
using a hot homogenization technique for effective AA delivery to cancer cells and eval-
uated their anticancer potential against the H-Ras 5RP7 cell line. Nano Zetasizer ZS and 
HPLC characterized spherical shapes of AA-SLNs with particle diameters ranging be-
tween 50–250 nm and having identical zeta potential. It was found that AA-SLNs released 
their content more steadily compared to free AA, releasing up to 70% during 96 h as com-
pared to approximately 90% of free AA released in 60 min. At 25 μM/mL concentrations, 
AA-SLNs exerted maximum cytotoxic effects with 41% cell viability towards H-Ras 5RP7 
cells by accumulating up to 68.5% of active caspase-3 content in cells investigated with 
AA-SLNs as compared to 40.5% active caspase-3 by AA after 72 h. In addition, AA-SLNs 
exerted no significant cytotoxicity towards control line NIH/3T3 cells [113].  
Sawant et al. in 2010 prepared liposomal nanoparticles of palmitoyl ascorbate (PA) 
and evaluated their in vitro and in vivo anticancer potential against murine mammary 
carcinoma 4T1 cells. Dynamic light scattering (DLS) revealed the 146.6 ± 29.0 nm particle 
size of the PA liposomes. In vitro study indicated that the generation of superoxide en-
hanced the anticancer potential of PA liposomes. Additionally, the in vivo study on 4T1 
tumour-bearing mice showed that PA liposomes at 20 mg/kg doses suppressed the tu-
mour growth remarkably compared to paclitaxel liposomes [114]. 
Martins et al. in 2010 prepared ascorbic acid capped nanoparticles of poly-D, L-(lac-
tide-co-glycolide) containing violacein and also evaluated their antitumor activity against 
leukaemia HL-60 cells. Photon correlation spectroscopy determined the spherical shape 
of the nanoparticles with diameters ranging from 300 to 550 nm and a solid identical neg-
ative Zeta potential. In the violacein release kinetics assay, at the initial 3 hours of analysis, 
an early burst of nanoparticles was observed, releasing 40–60% of drugs tailed by a steady 
release of up to 80% after 72 h of analysis. The results of MTT assays showed that the AA-
violacein nanoparticles exerted better cytotoxicity against HL-60 cells with an IC50 value 
of 0.2 μM, which was 2.5 times more active than free violacein (IC50 = 0.5 μM) [115]. 
Frungillo et al. in 2009 prepared nanoparticles loaded with trans-dehydrocrotonin 
(DHC) and L-ascorbic acid 6-stearate (AAS) and evaluated their in vitro antitumoral ac-
tivity against HL60 cells. Photon correlation spectroscopy determined that their dimen-
sions ranged between 110 to 140 nm with identical negative zeta potential. Kinetics assay 
of in vitro release revealed that free DHC solubilized after only 6 h of analysis. In compar-
ison, the nanoparticles loaded with AAS and DHC (NP-AAS-DHC) showed a steady re-
lease up to 72 h. The cytotoxic effects of NP-AAS-DHC on HL-60 cells were assessed by 
MTT and Trypan blue exclusion assay, revealing an IC50 of 140 and 90 μM, respectively 
[116]. 
7. Patents as an Anticancer Agent  
In the last few decades, several fundamental discoveries have been transformed into 
intellectual property with exceptionally realistic opportunities for future utilization. Con-
sequently, new and innovative products and technologies related to the anticancer 
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potential of ascorbic acid and its derivatives were patented. Following are some examples 
of such patents (Table 1): 
Table 1. List of some patents related to anticancer activity of ascorbic acid and its derivatives. 
S. No Invention Disclosed Patent Application Number References 
1 
A patent was filed to present an invention com-
prising nucleobase or its derivatives or its ana-
logues and an ascorbic acid molecule or its de-
rivatives or its analogues, attached together 
with or without oxygen bond in-between to 
form a single molecule. Once administered, it is 
expected to exert antiviral and anticancer effect 
PCT/IB20 17/057270 [117] 
2 
A patent was filed for the preparation method 
of novel 3-O-(p-mesylate benzyl)-ascorbic acid 
as an anticancer agent 
CN201710195165A [118] 
3 
An acylation derivative of L-ascorbic acid, 
wherein hydroxyl functionality bound to sec-
ond place carbon of L-ascorbic acid is substi-
tuted by a substituent capable of being de-
graded in vivo and being converted into a hy-
droxyl group or is unsubstituted, and a hy-
droxyl group bound to the position 6 of L-ascor-




The patent was filed for a composition of poly-
phenol and ascorbic acid or its derivatives for 
aiding in anticancer therapy. Polyphenol with 
an amount of 50.0–99.9 parts by weight and 
ascorbic acid or its derivatives in an amount of 
0.1–50.0 parts by weight, extraordinarily im-
proved anticancer effects of conventional anti-




A patent was filed to present the invention of a 
pharmaceutical preparation comprising L- 
ascorbic acid derivative with anti-malignant tu-
mour agent, which can be used to treat cancer 
EP98106276A [121] 
8. Challenges and Current Status 
To utilize ascorbic acid, stability is a major challenge as it is simply degraded on ex-
posure to high pH, aqueous mediums, oxygen, and metal ions. To improve its stability, 
some modifications have been made to ascorbic acid molecules to generate stable ascorbic 
acid derivatives such as L-ascorbyl-6-palmitate, L-ascorbic acid 6-phosphate, and L-ascor-
bic acid 2-glucosidase. Despite being more stable than the parent compound, they do not 
have direct antioxidant activity and require in vivo enzymatic conversion to L-ascorbic 
acid. When used topically, these derivatives also have lower permeability through the 
skin compared to their parent compound, ascorbic acid [111].  
At the recommended dose, ascorbic acid is safe in healthy individuals; the recom-
mended daily dietary dose of vitamin C is approximately 100 mg. However, in critically 
ill patients, vitamin C dosing is still a matter of concern [122]. 
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There have been documented cases that daily intake greater than 2 g/day can induce 
oxalate crystal nephropathy. In some cases, it was also observed that intake as low as 480 
mg/day orally or a single dose of 45 mg intravenously can induce oxalate crystal nephrop-
athy [123]. In individuals with a history of kidney stones, amounts greater than 1 g/day 
significantly raise the risk of kidney stone recurrence [124]. During the metabolic process, 
ascorbic acid breaks down in tissues to dehydroascorbic acid, then to diketogulonic acid, 
and is ultimately catabolized to oxalate, which is excreted in urine [125]. The supersatu-
rated oxalate in the tubules favourably deposits as crystals, developing into stones that in 
turn damage the tubular epithelium [122,123]. Ascorbic acid-induced oxalate nephropa-
thy can lead to severe consequences, including chronic renal disease necessitating long-
term dialysis or transplantation, and even death [123]. The duration and dose of ingested 
ascorbic acid in patients with underlying disease influences the development of acute kid-
ney injury. 
Globally, the ascorbic acid market was valued at USD $1273.05 million in 2020, and 
in the period from 2020 to 2027, it is expected to expand with a compound annual growth 
rate of 4.6% [126]. As per the report of 2016, the pharmaceutical industry accounted for 
about 30% of total demand for ascorbic acid. [127].  
9. Future Prospects and Conclusions 
Cancer is the second leading cause of death worldwide, and numerous approaches 
as well as materials are being explored to address this deadly disease. In this context, 
ascorbic acid has recently emerged as a prospective candidate. The potential functions of 
ascorbic acid covered above are associated with sufficient contact of ascorbate with tu-
mour cells in the tumour environment through effective distribution [59]. Thus, a high 
dose of ascorbic acid is important for exerting the anticancer effect. However, it should 
not be viewed as a universal model for cancer treatment [66]. Understanding the pharma-
cokinetics of ascorbate distribution into the tumour cells is vital for the planning of clinical 
trials and support for novel ascorbate treatments [59,66], as oral and intravenous admin-
istration result in different plasma pharmacokinetics [76]. A number of case studies and 
clinical trials on cancer patients have described that ascorbic acid at high doses, alone, or 
in combination with chemotherapies improves the quality of life with less toxicity 
[128,129]. Vitamin C hinders cancer progression by targeting different vulnerable nodes 
such as HIF, GLUT1 [46,59,66], and TET [130,131]. For a long period, ascorbic acid and its 
derivatives have been controversially cited as potential anticancer agents. Wang et al. ob-
served that in a phase 1 clinical study of patients with gastric and metastatic colorectal 
cancer, a high dose of ascorbic acid with other anticancer agents demonstrated potentially 
improved efficacy with suitably reduced side effects, enhancing the patient’s quality of 
life [132]. Lv et al., in their retrospective study on post-surgical hepatocellular carcinoma 
patients, observed that administration of intravenous ascorbic acid prolonged disease-free 
survival [133]. Zhao et al., in a clinical study of elderly patients with acute myeloid leu-
kaemia, witnessed that ascorbic acid with other anticancer agents had a better rate of com-
plete remission (CR) and overall survival without any substantial toxicity as compared to 
the anticancer agents alone [134]. Macan et al. developed two sequences of 6-(1,2,3-tria-
zolyl)-2,3-dibenzyl-L-ascorbic acid analogues, which displayed strong cytostatic activity 
against breast adenocarcinoma cell lines without any substantial toxicity towards normal 
fibroblasts [90]. Similarly, Harej et al. developed new 4-substituted 1,2,3-triazole L-ascor-
bic acid analogues that exhibited the highest antiproliferative activity towards breast ad-
enocarcinoma cells with greater cytotoxicity than one of the reference compounds, car-
boxyamidotriazole [91]. 
At present, several preclinical and clinical examinations have pointed to the ability 
of parenteral ascorbate to act synergistically with chemo or radiotherapy without any in-
terference [135–137], in turn enhancing cancer patients' quality of life by protecting normal 
tissues from damage caused by chemotherapy [138]. Thus, high-dose intravenous ascor-
bate and its derivatives signify an inexpensive alternative to anticancer therapy. 
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Moreover, they should be further explored as potential anticancer agents in clinical trials 
either alone or in combination, given their low toxicity, ready availability, and low cost. 
Although the anticancer potential of ascorbic acid was reported a half-century ago, 
much of its mechanism associated with anticancer activity has remained obscure. How-
ever, some findings in recent years have extended our understanding of the biological 
functions and mechanism of involvement of ascorbate in cancer therapy as an anticancer 
agent, underlining a range of interesting and promising hypotheses that suggest there is 
a good basis for using ascorbate in cancer treatment. Ascorbic acid has a critical role in the 
function of HIFs, TETs, GLUT-1, FIHs, and PHDs, which are fundamentally involved in 
cancer development and progression. Discovering the pathways regulated by ascorbate 
will facilitate progress in the development of innovative treatments to sensitize tumours 
to ascorbic acid use. We have reviewed some of the reported novel ascorbic acid deriva-
tives as anticancer agents, and it was observed that some of the derivatives were compa-
rable to standard drugs used in the experiments with lower toxicity to no toxicity towards 
normal human cells. 
High-dose intravenous ascorbate and its derivatives have the potential to deliver fa-
vourable and economical anticancer therapeutic opportunities that should be further ex-
plored. Due to their ready availability in nature, low toxicity, and low cost, ascorbic acid 
and its derivatives could become important therapeutic options in our battle against can-
cer. However, we will need to pursue conclusive answers on the clinical benefits of ascor-
bic acid in the treatment of cancer. 
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GLUT Glucose transporter  
HIF  Hypoxia-inducible factor  
TET  Ten-eleven translocation  
FIH  Factor Inhibiting HIF  
PHD  Prolyl hydroxylase domain enzyme  
VHL  von Hippel-Lindau  
DHA  Dehydroascorbate  
NADPH  Nicotinamide adenine dinucleotide phosphate  
GSH  Glutathione  
GSSG  Glutathione disulphide  
NADP  Nicotinamide adenine dinucleotide phosphate  
PARP  Poly (ADP- ribose) polymerase  
NAD  Nicotinamide adenine dinucleotide  
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
NAM  Nicotinamide  
5mC  5-methylcytosine  
5hmC  5-hydroxymethylcytosine  
5fC  5-formylcytosine  
5CaC  5-carboxylcytosine  
AML  Acute myeloid leukaemia  
CMML  Chronic myelomonocytic leukaemia 
Fe2+/α-KGDD  Iron/α-ketoglutarate-dependent dioxygenases  
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ROS  Reactive oxygen species  
HNE  4-hydroxynonenal  
AscH− Ascorbate  
Asc⋅−  Ascorbate free radical  
H2O2  Hydrogen peroxide  
HO⋅  Hydroxyl peroxide radical  
MTX  Mitoxantrone 
PA  Palmitoyl ascorbate  
DOX  Doxorubicin  
DC  Docetaxel  
EPI  Epirubicin  
PTX  Paclitaxel  
TEM  Transmission electronic microscopy  
SLN  Solid lipid nanoparticle  
DLS  Dynamic light scattering  
DHC  trans-dehydrocrotonin  
AAS  L-ascorbic acid 6-stearate 
5-FU  5-fluorouracil  
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